2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3105

Relationships Between a Serum Biomarker of B Cell Differentiation and B Cell Activating Factor Suggest Possible Distinct Pathways of Response to Rituximab in Patients with Systemic Lupus Erythematosus
Abstract Number: 3106

A Simple Test for Assessing and Monitoring SLE Disease Activity Status
Abstract Number: 3107

Switching from Anabolic to Catabolic Metabolism – a Novel Immunomodulatory Therapy in RA
Abstract Number: 3108

Citrullinated Aggrecan Peptides Are Targets of Auto-Reactive CD4+ T-Cells in Rheumatoid Arthritis
Abstract Number: 3109

Regulatory T Cells Deficient in Protein Phosphatase 2A Lose Suppressive Function and Convert to an Effector Phenotype
Abstract Number: 3110

Rab4A Is Required for Development of Tregs, Restricts Antiphospholipid Antibody Production and Pro-Inflammatory Expansion of Macrophages and Neutrophils, and Blocks Pristane-Induced Intra-Alveolar Hemorrhage in a Mouse Model of SLE
Abstract Number: 3111

Pathogenic T Cell Responses in Systemic Sclerosis Is Shaped By Novel Cytokine Axis in the Microenvironment: A Multidimensional, High Throughput Analysis
Abstract Number: 3112

DOCK8 Associates with STAT5 and Promotes Regulatory T Cell Function
Abstract Number: 3113

Evaluation of a Clinical Transition Pathway for Adolescents with Autoimmune Diseases
Abstract Number: 3114

Cardiorespiratory Fitness in Children with Juvenile Idiopathic Arthritis Treated in the Biological Era Is Comparable with Controls- a Cross-Sectional Study
Abstract Number: 3115

Reconsidering the Juvenile Idiopathic Arthritis Core Set: How Patients and Caregivers Define Disease Activity
Abstract Number: 3116

Risk of Infections in Juvenile Idiopathic Arthritis Patients Treated with Biologic Agentsand/or Methotrexate: Results from Pharmachild Registry
Abstract Number: 3117

Development of Autoimmune Diseases and Genetic Predisposition in Children with Neonatal Lupus and Their Unaffected Siblings
Abstract Number: 3118

Differences in Disease Phenotype, Management and Outcomes of Children with Juvenile Idiopathic Arthritis throughout the World – Analysis of 8,325 Patients Enrolled in the Epoca Study
Abstract Number: 3119

Complete Whole Genome Transcriptome, DNA Methylation, and Histone Mark Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Reveals a Distinctive Epigenetic Landscape and Critical Pathogenic Pathways

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].